On behalf of the 7th MIM local organizing committee, the MIM Secretariat and the Conference Scientific committee, we are pleased to announce that the abstract, symposium and exhibition submission deadline has been extended to October 31st, 2017 in response to numerous requests and due to the increased interest in the upcoming 7th MIM conference.
A word from one of our keynote speakers at the MIM2018 , Prof. Peter Agre : 2003 Nobel prize recipient in Chemistry. “My sense tells me that this would be an opportunity to meet many young scientists, that I’ve never met previously, and who are doing important work, particularly work relevant to the problems in Africa.”
A word from one of our keynote speakers at the MIM2018, Dr. Thomas Kariuki : Director of Alliance for accelerating Excellence in Science in Africa (AESA) & African Academy of Sciences (AAS). “Congratulations to the University Cheikh Anta Diop (UCAD) for being chosen to host the MIM conference, that’s excellent news for Senegal, and I’m looking forward to participating in the meeting.”
We are very pleased to provide you with more information about our lineup of esteemed Keynote Speakers at the upcoming 7th MIM Pan African Malaria Conference!
20 years after the first MIM conference, Senegal will host the 7th edition, in Dakar, at the International Conference Centre Abdou Diouf on April 15-20, 2018.
Twenty years after the first MIM Conference which drew attention to major questions for malaria research, and identify ways to strengthen and sustain the research capacity of malaria endemic countries in Africa, several countries in Africa are now engaging towards malaria elimination. Focus in Senegal, the first country report in the Roll Back Malaria Progress & Impact series describes how Senegal achieves a spectacular drop in its malaria burden.
Thank you MP for your blog http://mosquitopundit.net/mosquitopundit-blog/act-and-malaria-recrudesce....
You give me a lot of credit when you state: malaria researcher Irene Teis doesn’t know that her 2 April 2016 post “Was the Nobel prize for artemisinin a fatal error” at www.malariaworld.org helped save at least nine lives.
Interceptor® G2 launches a new chapter in the fight against malaria and insecticide resistance. It is a new insecticide-treated mosquito net that we started working on with the IVCC and the London School of Hygiene & Tropical Medicine more than a decade ago.
Received from Emile Schmitz, Martelange
The occurrence of Plasmodium vivax in bone marrow/spleen has been reported by various authors (including Baro, del Portillo, Lacerda, Marti, Obaldia, Siqueira and Wirth). It is not apparent from the title, but some of the implications hereof are discussed in the 2017 article on “Malaria Eradication and the Hidden Parasite Reservoir” (click here).
A new blood-stage parasite question has arisen. Are erythrocytic forms in bone marrow/spleen part of the hidden Plasmodium vivax reservoir? Do they cause or contribute to renewed or increased peripheral parasitaemia? (Link to the article on the subject [click here]).
While the malaria death count in Cambodia dropped to just one case in 2016, a new threat to the race against the disease arises in south-eastern Asia: superbugs. A superbug is a drug-resistant, human-killing parasite that modern medicine struggles to combat.
In a current paper in the Journal of Infectious Diseases, recently reviewed at Global Health Technology Review, Dr. Jonathan Parr (University of North Carolina) examines cases of RDT-negative P.falciparum cases as part of the Demographic Health Survey of Democratic Republic of the Congo.
What has happened to various hypnozoite-associated (in one way or another) personalities from the late 1970s and the 1980s, when the malarial hypnozoite was "accidentally" discovered, is not widely known. People occasionally enquire about these individuals. Some, such as M.R. Hollingdale, R.E. Sinden, G.A.T. Targett and M.B.
I have just posted the attached concept note entitled "Promoting south-centred collaborations in vector-borne diseases" on the extranet discussion board for the following UK-BBSRC funding mechanism to support networks in vector-borne disease (VBD) research:
Are hypnozoites the only source of relapse-like, recurrent Plasmodium vivax malaria? They might not be. See explanation here [click] (however, note from the website link provided in a response to the blog, the new angle re erythrocytic parasites that was published online on 30 March 2017).
When analysing results obtained in genetic epidemiological studies, how can homologous recurrences of Plasmodium vivax malaria be explained? Link to a blog on the subject [click] (but see, via the website given in one of the blog responses, the new analysis concerning erythrocytic parasites that was published online on 30 March 2017).
The presumed hypnozoite reservoir is perceived to be a threat to the goal of eradicating human malaria. However, the same now applies to putative non-hypnozoite tissue stages as well, notably quiescent merozoites. Persistence of extra-vascular tissue merozoites in vivax malaria has on genetic grounds been suspected since 2011. So far, they have been parasitologically demonstrated in rodent malarial infections. There is no particular reason why they should not also occur in primate malaria of various kinds.
Speculative extrapolation from biological and genetic findings resulting from malarial research carried out in recent years, places in doubt aspects of the validity of the current concept of hypnozoite-mediated malarial relapse, entrenched though the hypothesis (usually stated by authors as a fact) is. A piece(s) of the puzzle might be missing.
A little waterbird (or was it a frog?) whispered in my ear. Aquatic organisms don’t want humans to destroy their habitats when trying to eliminate malaria. Draining of swamps, for example, would have negative consequences not only for mosquitoes but also for various other (innocent) creatures that live there. Where does this leave malariologists, so to speak? Just asking.
New Method under ultrasound for rapid extraction and efficient purification of the antimalarial drug "Artemisinin" from medicinal plants.
Free download from Elsevier available till July 30th : http://authors.elsevier.com/a/1TBDt4p3AWHr29
Early recurrences (which are often homologous) in treated Plasmodium vivax infections are usually considered to be hypnozoite-mediated relapses. Can such recurrences sometimes or frequently be, instead, recrudescences caused by reactivation of blood stages that became temporarily quiescent following drug exposure? The experimental background to this question is given here.
Therapeutic failure of primaquine in cases of Plasmodium vivax malaria is often noted by clinicians. A newly recognized, possible cause of such treatment failure is the reactivation of viable dormant parasites that might be present in one or more extra-hepatic and extra-vascular sites. Administration of primaquine will not necessarily result in these stages being killed. Here is the link to where this drug-associated matter is discussed.